AVTX - Avalo Therapeutics Inc
IEX Last Trade
7
-2.050 -29.286%
Share volume: 71,448
Last Updated: Fri 30 Aug 2024 09:59:24 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$9.05
-2.05
-22.65%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-04 | 2022-11-07 | 2023-03-29 | 2023-05-04 | 2023-08-03 | 2023-11-09 | 2024-03-29 | 2024-05-13 | |
| Assets | |||||||||
| Total Assets | 32.224 M | 36.547 M | 33.367 M | 36.235 M | 24.235 M | 29.270 M | 20.993 M | 123.728 M | |
| Current Assets | 15.021 M | 19.450 M | 16.416 M | 19.253 M | 7.519 M | 12.659 M | 8.395 M | 111.213 M | |
| Inventories | 23.000 K | 22.000 K | 20.000 K | 19.000 K | 18.000 K | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 3.191 M | 2.432 M | 3.209 M | 2.484 M | 1.141 M | 2.478 M | 979.000 K | 1.032 M | |
| Short Term Investments | 3.191 M | 2.432 M | 3.209 M | 2.484 M | 1.141 M | 2.478 M | 979.000 K | 1.032 M | |
| Total Receivables | 544.000 K | 0.000 | 0.000 | 0.000 | 38.000 K | 0.000 | 0.000 | 0.000 | |
| Current Cash | 11.249 M | 16.943 M | 13.172 M | 16.687 M | 6.307 M | 10.180 M | 7.415 M | 110.177 M | |
| Total Non-current Assets | 17.203 M | 17.097 M | 16.951 M | 16.982 M | 16.716 M | 16.611 M | 12.598 M | 12.515 M | |
| Property Plant Equipment | 2.567 M | 2.507 M | 2.411 M | 2.442 M | 2.176 M | 2.071 M | 1.965 M | 1.882 M | |
| Other Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 14.409 M | 14.409 M | 14.409 M | 14.409 M | 14.409 M | 14.409 M | 10.502 M | 10.502 M | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 32.224 M | 36.547 M | 33.367 M | 36.235 M | 24.235 M | 29.270 M | 20.993 M | 123.728 M | |
| Total liabilities | 38.175 M | 38.575 M | 44.282 M | 42.502 M | 31.204 M | 14.575 M | 13.689 M | 224.813 M | |
| Total current liabilities | 15.395 M | 18.149 M | 22.114 M | 23.245 M | 22.454 M | 6.005 M | 4.618 M | 215.700 M | |
| Accounts Payable | 2.164 M | 1.447 M | 2.882 M | 5.565 M | 751.000 K | 789.000 K | 446.000 K | 916.000 K | |
| Other liabilities | 3.939 M | 3.791 M | 8.541 M | 8.639 M | 8.594 M | 8.406 M | 8.916 M | 8.951 M | |
| Current long term debt | 0.000 | 2.564 M | 5.930 M | 9.296 M | 14.115 M | 0.000 | 0.000 | 0.000 | |
| Long term debt | 18.713 M | 16.502 M | 13.486 M | 10.470 M | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 3.939 M | 3.791 M | 8.541 M | 8.639 M | 8.594 M | 8.406 M | 8.916 M | 8.951 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | -5.951 M | -2.028 M | -10.915 M | -6.267 M | -6.969 M | 14.695 M | 7.304 M | -101.085 M | |
| Common stock | 9.401 M | 9.413 M | 9.420 M | 11.723 M | 13.972 M | 46.764 M | 1.111 B | 859.381 K | |
| Retained earnings | -297.204 M | -294.012 M | -303.824 M | -313.779 M | -321.738 M | -326.966 M | -335.134 M | -456.424 M |